New clinical practice data for Bial's Zebinix

7 June 2019
bial_big

Portugal’s Bial and Japan-based licensee Eisai (TYO: 4523) have announced new clinical practice data from the Euro-Esli study of Zebinix (eslicarbazepine acetate).

The trial demonstrates safety and clinical effectiveness as an adjunctive therapy in people with focal epilepsy and with psychiatric co-morbidities, including intellectual disability, compared with people with no psychiatric co-morbidities.

At 12 months, the responder rate was  83.1% and the seizure freedom rate was 51.3%, compared with 82.5% and 51.4% respectively, for people without psychiatric comorbidities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical